Rafael Holdings, Inc. (RFL) AI Stock Analysis

Rafael Holdings, Inc. is a diversified enterprise operating across clinical and early stage pharmaceutical development and commercial real estate assets located in the United States and Israel. In its Healthcare segment, the company develops treatments targeting metabolic differences between normal cells and cancer cells, led by flagship drug candidate CPI-613 (devimistat), which is in Phase III trials for metastatic pancreatic cancer and acute myeloid leukemia. In its Real Estate segment, the company manages commercial properties across the United States and Israel to provide operational stability. Founded in 2017 and based in Newark, New Jersey, the firm had 21 employees as of its 2018 initial public offering record.

Rafael Holdings recorded trailing twelve month revenue of $980,000 through April 30, 2026, with quarterly revenue falling 50.6% year-over-year. Revenue over the five-year period from FY2020 to FY2025 declined at a compound annual rate of 28.5%. Annual revenue shifted from $802,000 in FY2021 to $410,000 in FY2022 and $279,000 in FY2023, before rebounding to $637,000 in FY2024 and $917,000 in FY2025. Gross margin contracted from 100.0% in FY2023 to 75.8% in FY2024 and 54.0% in FY2025. Operating margins remained deeply negative across this span, registering -2847.2% in FY2025 alongside a net loss of $30.5M, an EPS of -$1.04, and research and development expense of $12.8M.

As of April 30, 2026, Rafael Holdings held $30.5M in cash and short-term investments against total debt of $610,000, resulting in net cash of $29.9M. Shareholders' equity was $75.4M and total assets were $92.0M, supporting a current ratio of 3.16 and a debt-to-equity ratio of 0.01. In FY2025, operating cash flow was -$18.9M and free cash flow was -$18.9M. Capital expenditures totaled $4,000, while share issuance raised $25.0M, contributing to a 170.4% increase in share count over 5 years.

Rafael Holdings trades at a price-to-sales multiple of 73.8x and an enterprise value to revenue of 76.7x, compared to a price-to-sales multiple of 3.7x for the median of its US-listed Real Estate peers. Its EV to EBITDA ratio stands at 5.4x, below the peer median of 14.7x, while its price-to-book ratio is 1.4x. The stock closed at $1.39 on October 16, 2026, having produced a 1-year return of 4.5% compared to 16.8% for the S&P 500 (SPY). Over 5 years, the stock generated a return of -95.4%, trailing the 83.0% gain of SPY.

Wall Street coverage for Rafael Holdings does not feature active consensus rating tallies or mean price target figures. The company does not have published consensus revenue or earnings estimates on record. Investors tracking quarterly filings note that the next earnings date is scheduled for October 28, 2026. Historical earnings results reflect continuing losses, including an annual diluted EPS of -$1.04 in FY2025 and trailing twelve month EPS of -$0.72 as of the April 30, 2026 fiscal quarter.

This page is an AI-written research summary of Rafael Holdings, Inc. (RFL). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: RFL income statement, RFL balance sheet, RFL key metrics, RFL chart. See the RFL stock overview for the latest quote and news.